Article Text

Download PDFPDF

Guiding policy to reduce the burden of COPD: the role of epidemiological research
  1. Guy B Marks1,2
  1. 1 Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, Sydney, Australia
  2. 2 South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
  1. Correspondence to Dr Guy B Marks, Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, Sydney, NSW 2050, Australia; g.marks{at}unsw.edu.au

Statistics from Altmetric.com

In Thorax, Bhatt and colleagues’ interesting cross-sectional analysis of data from the COPDGene study cohort demonstrates, somewhat unsurprisingly, that the compound (multiplicative) measure of cumulative exposure to tobacco smoking, ‘pack-years’, is a suboptimal index of exposure with respect to effects on indices of airflow obstruction, spirometric lung volume and emphysema.1 This is unsurprising because there is no biological basis for assuming that the effects should be manifest by a simple multiplicative relationship between duration of smoking and estimated average number of cigarettes smoked per day. Compound measures are convenient, but usually not robust, measures for epidemiological investigation. This study confirms that it is almost always more appropriate (and powerful) to analyse the individual components of the exposure separately and to model the interaction between them.

Perhaps more surprising is the near absence of any effect of the estimated average number of cigarettes smoked per day on the spirometric and radiological endpoints. The authors offer a number of plausible potential explanations for this negative finding. These include methodological limitations: non-differential measurement error in the estimation of number of cigarettes smoked per day and the limited variation in number of cigarettes smoked per day in the study population. All participants in the COPDGene cohort study were current or ex-smokers with at least 10 pack-years of smoking history. It is also likely that the method of recruitment may have favoured people with symptoms of lung disease, though those with diagnosed lung disease other than COPD and asthma were excluded. This could have further limited the range of variability in the data. There are also potential biological explanations for the lack of association with number of cigarettes smoked, including the propensity of individuals to inhale more deeply when they smoke fewer cigarettes (or when they smoke cigarettes with a lower nicotine content).2 It is for this reason that it is inappropriate to use the short-hand term ‘smoking intensity’ to describe the number of cigarettes smoked per day.

The major question raised by this article is: where should we go from here? Good quality evidence of a likely causal association between smoking and death due to COPD has been available for at least 40 years.3 There is little doubt about the need for policy and practice to prevent smoking uptake and assist in cessation. It seems unlikely that this will be changed by further research on the dose–response relation for smoking and COPD. WHO’s Framework Convention for Tobacco Control, which has been ratified by 180 parties representing 90% of the world’s population,4 charts a pathway for global action. It is summarised as MPOWER5 and includes a range of strategies suitable for implementation by clinicians and government agencies, including health promotion and advocacy (including opportunistic brief advice by clinicians), taxation policy, restrictions on smoking in public places including workplaces, restaurants and hospitals, banning all tobacco promotion (including the introduction of plain packaging), support for quit attempts and monitoring and evaluation. There is an important role for the lung health community in engaging with, and supporting, this global campaign. In some countries, there has been substantial progress, with associated health benefits,6 but in much of the world there is a great deal still to do to achieve these benefits.7 Furthermore, the tobacco industry has fought tenaciously to defend its commercial interests, both overtly8 and covertly.9 These efforts must be strenuously resisted.

There is an important role for further epidemiological research on COPD, but probably there is little to be gained by further interrogating the role of smoking in causing this disease. Instead, we need to focus on the importance of other, potentially avoidable, causes of COPD, including occupational exposure to dust and fumes,10 indoor and outdoor air pollution,11 early-life nutrition12 and respiratory infections, including tuberculosis.13 A better understanding of exposure–response functions for these exposures should lead to cluster-randomised controlled trials of community-level interventions, designed to establish the role of such interventions in preventing the development of chronic lung disease. Together with ongoing concerted action against the scourge of tobacco, this pathway for research promises to lead to a world that will breathe more easily.

References

View Abstract

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles